Sun Feels The Heat As FDA Seizes Caraco Drugs; To Sign Consent Decree And Reset Guidance
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Days after U.S. FDA ordered seizure of 33 products from Caraco's Detroit-based manufacturing unit, its Indian parent Sun Pharma told investors that it will withdraw its earnings guidance and revise at a later date. Sun Pharma had set a guidance of 13-15 percent growth in 2009-10
You may also be interested in...
Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco
MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.
Once More Taro Takes Sun Pharma To Court; Alleges Failure To Disclose Information About U.S. FDA Action Against Caraco
MUMBAI - India's Sun Pharmaceutical has more court battles to deal with as its takeover target Taro Pharmaceutical of Israel has filed one more case in a New York court alleging that its bidder failed to disclose "material information to Taro shareholders and unlawful use of confidential information.
GMP Deviations Lead WHO To Issue "Notice Of Concern" To Matrix Labs; May Suspend Prequalified Anti-AIDS Products
MUMBAI - The Indian drug industry received another blow to its reputation when the World Health Organization issued a "Notice of Concern" to Hyderabad-based Matrix Labs, which is now 90 percent owned by Mylan, the third-largest generic drug maker in the world